Corbus Pharma (CRBP) Reports Complete Enrollment in NIH-Sponsored Phase 2 Study of Lenabasum for Treatment of Systemic Lupus Erythematosus streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Dermavant Sciences: Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that two abstracts from Dermavant s two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, will be presented during the upcoming American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021), on April 23-25, 2021.
Tapinarof is being developed as a novel, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA), cosmetically elegant, steroid-free topical cream for the treatment of plaque psoriasis and atopic dermatitis.
The following posters will be viewable on the conference platform for the entirety of the conference:
Will Psoriasis Patients Embrace Proactive Topical Therapy? medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
(1) In this collaboration Almirall will commercialize Wynzora Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply.
MC2 Therapeutics and Almirall partner to make Wynzora Cream a leading topical product for Plaque Psoriasis in Europe
In a large European based Phase 3 clinical trial (n=490), Wynzora Cream has demonstrated substantial efficacy with a PGA treatment success of 51% and beneficial treatment convenience
1 Cream has been filed and approval is expected this year
Almirall S.A. (BME: ALM), a global biopharmaceutical company and
MC2 Therapeutics, a commercial stage pharmaceutical company developing a new standard within topical therapies for autoimmune and chronic inflammatory conditions, announced today an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora
Almirall and MC2 Therapeutics enter a license, collaboration and commercialization agreement for European rights to Wynzora® Cream for treatment of plaque psoriasis
USA - English In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply MC2 Therapeutics and Almirall partner to make Wynzora® Cream a leading topical product for Plaque Psoriasis in Europe In a large European based Phase 3 clinical trial (n=490), Wynzora® Cream has demonstrated substantial efficacy with a PGA treatment success of 51% and beneficial treatment convenience[1] Marketing Authorization Application (MAA) in Europe of Wynzora® Cream has been filed and approval is expected this year